DUBLIN – Interleukin-15 (IL-15) inhibition is back on the menu. Calypso Biotech BV closed a €20 million (US$22.7 million) series A round to take what it claims is a best-in-class IL-15 antagonist, CALY-002, into clinical development for autoimmune disease.